PMID- 34790738
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220830
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 9
IP  - 20
DP  - 2021 Oct
TI  - Identifying potential therapeutic targets of Tang-Yi-Ping for the treatment of 
      impaired glucose tolerance: a tandem mass tag-labeled quantitative proteomic 
      analysis.
PG  - 1532
LID - 10.21037/atm-21-4257 [doi]
LID - 1532
AB  - BACKGROUND: This study uses the tandem mass tag (TMT)-labeled quantitative 
      proteomic analysis to identify potential therapeutic protein targets of a Chinese 
      prescription called Tang-Yi-Ping (TYP) for the treatment of impaired glucose 
      tolerance (IGT) in rats. METHODS: A total of 31 specific-pathogen free (SPF) male 
      Wistar rats were used in our study. Ten were randomly selected as a control 
      group, while 21 received a high-sugar and high-fat diet combined with an 
      intraperitoneal injection of streptozotocin to establish IGT subjects. After 
      eliminating 2 rats without successful modeling, 19 were randomly divided into a 
      TYP group (n=9) and IGT model group (n=10). The TYP group was given a TYP 
      decoction of 6.36 mg/kg-1/d-1. After 8 weeks of intervention, blood 
      glucose-related indicators were measured, and cell morphology was observed by 
      hematoxylin and eosin (HE) staining. TMT-labeled proteomic analysis was applied 
      to detect the differentially expressed proteins (DEPs) in the pancreases of the 
      three groups. The intersection of the DEPs in both the TYP group and IGT model 
      group underwent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes 
      (KEGG) pathway analyses to identify the related biological functions and signal 
      transduction pathways. Finally, western blot (WB) was used to verify the TMT 
      proteomics results. RESULTS: TYP can effectively reduce blood glucose and improve 
      islet morphology in IGT rats. We identified a total of 16 potential therapeutic 
      protein targets of TYP, 4 of which were upregulated, while 12 were downregulated, 
      including Rbp4, Fam3b, Flot2, etc. [fold change (FC) >1.1, P<0.05]. The 
      significant signal transduction pathways included arginine and proline 
      metabolism, glyceride metabolism, glycerophospholipid metabolism, mTOR, Wnt, and 
      insulin signaling pathways. CONCLUSIONS: For anti-IGT therapy, we found TYP 
      regulates 16 protein targets, multiple biological functions, and multiple signal 
      transduction pathways. This study thus makes a significant contribution to 
      identifying new potential therapeutic targets for treating IGT.
CI  - 2021 Annals of Translational Medicine. All rights reserved.
FAU - Li, Jie
AU  - Li J
AD  - College of the Second Clinical Medicine, Shandong University of Traditional 
      Chinese Medicine, Jinan, China.
AD  - Department of Endocrinology Medicine, the Second Affiliated Hospital of Shandong 
      University of Traditional Chinese Medicine, Jinan, China.
FAU - Bu, Shuai
AU  - Bu S
AD  - Department of Cardiovascular Medicine, the Second Affiliated Hospital of Shandong 
      University of Traditional Chinese Medicine, Jinan, China.
FAU - Zhou, Honglei
AU  - Zhou H
AD  - College of pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 
      China.
FAU - Bi, Siling
AU  - Bi S
AD  - Department of Cardiovascular Medicine, the Second Affiliated Hospital of Shandong 
      University of Traditional Chinese Medicine, Jinan, China.
FAU - Xu, Yunsheng
AU  - Xu Y
AD  - Department of Endocrinology Medicine, the Second Affiliated Hospital of Shandong 
      University of Traditional Chinese Medicine, Jinan, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC8576661
OTO - NOTNLM
OT  - Impaired glucose tolerance (IGT)
OT  - Tang-Yi-Ping (TYP)
OT  - protein targets
OT  - tandem mass tag proteomics (TMT proteomics)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at https://dx.doi.org/10.21037/atm-21-4257). The authors have no 
      conflicts of interest to declare.
EDAT- 2021/11/19 06:00
MHDA- 2021/11/19 06:01
PMCR- 2021/10/01
CRDT- 2021/11/18 07:02
PHST- 2021/08/05 00:00 [received]
PHST- 2021/10/09 00:00 [accepted]
PHST- 2021/11/18 07:02 [entrez]
PHST- 2021/11/19 06:00 [pubmed]
PHST- 2021/11/19 06:01 [medline]
PHST- 2021/10/01 00:00 [pmc-release]
AID - atm-09-20-1532 [pii]
AID - 10.21037/atm-21-4257 [doi]
PST - ppublish
SO  - Ann Transl Med. 2021 Oct;9(20):1532. doi: 10.21037/atm-21-4257.